Efficacious, affordable Viral Vaccines
Novel, efficacious, and affordable vaccines for the world
Vision
To develop and bring next-generation respiratory vaccine technology to those in need, transforming cutting-edge Indian science into globally accessible disease protection
Problem
Respiratory viral infections cause severe global health crises, disproportionately devastating vulnerable populations in India and low-resource nations due to high treatment costs and inadequate access to efficacious vaccines
Solution
Our proprietary, patented technology designs highly stable, efficacious antigens, enabling the scalable manufacturing and affordable global delivery of powerful vaccines against lethal respiratory viral infections
Potential
Over the next decade we aim to deliver billions of affordable Mynflu001 doses annually, significantly reducing the 300,000-650,000 global deaths from seasonal influenza.
Target Beneficiaries
We are solving for a global problem, with a focus on vulnerable populations and low-income communities in India and other LMICs
Current Users
We have completed early clinical trials in Australia and safety-tox studies in India, paving the way for upcoming clinical trials in collaboration with the Indian Council of Medical Research (ICMR)
